4 The ACC document additionally provided a series of opportunities in which clinicians may consider starting a GLP-1 RA or an SGLT-2 inhibitor with demonstrated cardiovascular benefit 4 : In a patient with T2D and ASCVD
Retatrutide (also known as LY3437943) is an investigational injectable medication currently being evaluated in registered clinical trials for the management of obesity and type 2 diabetes
Therefore, exploring the potential of L-carnitine in improving complications among preterm infants and their corresponding short- and long-term outcomes may provide new interesting research opportunities toward further optimizing the treatment of preterm infants
However, an effort to change this and allow Medicare to cover obesity medications is within the Federal Treat and Reduce Obesity Act legislation (see sidebar Resources).1 Reference 1
If weight loss is your main goal, ask your provider about higher-dose weight management protocols
This can sometimes, paradoxically, improve your thyroid function by reducing the T4 substrate